cytori_8k081612.htm
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

Current Report 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  August 16, 2012

CYTORI THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
 

Delaware
001-34375
33-0827593
(State or Other Jurisdiction of Incorporation)
(Commission File
Number)
(I.R.S. Employer Identification Number)

3020 Callan Road, San Diego, California 92121
(Address of principal executive offices, with zip code)

(858) 458-0900
(Registrant's telephone number, including area code)

n/a
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 
 □
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
 
 □
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
 
 □
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
 
 □
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

Item 5.07                      Submission of Matters to a Vote of Security Holders

(a)  
On August 16, 2012, Cytori Therapeutics, Inc. (the “Company”) held its Annual Meeting. The Company filed its definitive proxy statement for the proposals voted upon at the annual meeting with the Securities and Exchange Commission on April 30, 2012.

(b)  
As of June 20, 2012, the record date for the annual meeting, 58,706,856 shares of the Company’s common stock were issued and outstanding. A quorum of 47,563,758 shares of common stock were present or represented at the annual meeting. The following items of business were voted upon by stockholders at the annual meeting:

1.  
Election of Directors. The following members of the Board of Directors were elected to serve until the 2013 annual meeting of stockholders and until their respective successors are elected and qualified,  as follows:

 
VOTES FOR
WITHHOLD AUTHORITY
Lloyd H. Dean
18,827,283
944,653
Christopher J. Calhoun
18,200,252
1,571,684
Richard J. Hawkins
15,636,919
4,135,017
Paul W. Hawran
15,624,471
4,147,465
Marc H. Hedrick, M.D.
18,803,726
968,210
Ronald D. Henriksen
17,335,135
2,436,801
E. Carmack Holmes, M.D.
18,803,094
968,842
David M. Rickey
17,328,605
2,443,331
Tommy G. Thompson
18,508,758
1,263,178

Broker Non-Votes: 27,791,822

2.  
Ratify Independent Registered Public Accountants.  The appointment of KPMG LLP, independent registered public accountants, to act as our independent auditors for the fiscal year ending December 31, 2012 was ratified, as follows

FOR
AGAINST
ABSTAIN
 
45,702,346
 
847,223
 
1,014,189

Broker Non-Votes: 0

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.




 
CYTORI THERAPEUTICS, INC.
   
Date:  August 20, 2012
By: /s/ Mark E. Saad
 
Mark E. Saad
 
Chief Financial Officer